Dishman Carbogen Amcis is a contract manufacturer based in India. It holds 11 active US drug master files across a filed portfolio of 15 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 12 June 2025 as NAI. Customs aggregates show $28.9M of exports covering 396 molecules to 49 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Ahmedabad, India | 3004161218 |
| Ahmedabad, India | 1000607691 |
| Molecule | Regulators | Docs |
|---|---|---|
| Bupivacaine | US FDA | 2 |
| Cetylpyridinium | SFDA (Saudi Arabia), US FDA | 2 |
| Pralidoxime | SFDA (Saudi Arabia), US FDA | 2 |
| Ropivacaine | SFDA (Saudi Arabia), US FDA | 2 |
| Bisacodyl | US FDA | 1 |
| Bosentan | SFDA (Saudi Arabia) | 1 |
| Cetrimide | US FDA | 1 |
| Cetylpiridinium | SFDA (Saudi Arabia) | 1 |
| Dimethyl | SFDA (Saudi Arabia) | 1 |
| Eprosartan | US FDA | 1 |
| Indigotindisulfonic Acid | US FDA | 1 |
| Isosulfan Blue | US FDA | 1 |
| Sodium Picosulfate | US FDA | 1 |
| Sodium Picosulphate | SFDA (Saudi Arabia) | 1 |
| Valganciclovir | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 2 |
| EMA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $2.6M | 31 |
| 2025 | $311.2M | $28.9M | 49 |
| 2024 | $312.6M | $31.6M | 50 |
| 2023 | $292.2M | $31.3M | 54 |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Choose your molecules and target markets. Dishman Carbogen Amcis comes back tiered against every other supplier able to file there.
Start for free